Drug Name



Drug Name |Dosage & Route |Action |Indication |Adverse Effects |Contraindication |Nursing Responsibility | |

EPINEPHRINE

(ep-i-ne'frin)

Bronkaid Mist, Epi-E-Zpen, Epinephrine Pediatric, EpiPen Auto-Injector, Primatene Mist Suspension

Classifications: autonomic nervous system agent; alpha- and beta-adrenergic agonist; bronchodilator

|

Anaphylaxis

Adult: SC 0.1–0.5 mL of 1:1000 q10–15min prn IV 0.1–0.25 mL of 1:1000 q10–15min

Child: SC 0.01 mL/kg of, 1:1000 q10–15min prn IV 0.01 mL/kg of 1:1000 q10–15min

Neonate: IV Intratracheal 0.01–0.03 mg/kg (0.1–0.3 mL/kg of 1:10,000) q3–5min prn

Cardiac Arrest

Adult: IV 0.1–1 mg (1–10 mL of 1:10,000) q5min as needed Intracardiac 0.1–1 mg

Child: IV 0.01 mg/kg (0.1 mL/kg of 1:10,000) q5min as needed Intracardiac 0.05–0.1 mg/kg

Asthma

Adult: SC 0.1–0.5 mL of 1:1000 q20min–4h Inhalation 1 inhalation q4h prn

Child: SC 0.01 mL/kg of 1:1000 q20min–4h Inhalation 1 inhalation q4h prn |

Naturally occurring catecholamine obtained from animal adrenal glands; also prepared synthetically. Acts directly on both alpha and beta receptors; the most potent activator of alpha receptors. Strengthens myocardial contraction; increases systolic but may decrease diastolic blood pressure; increases cardiac rate and cardiac output.

|

Temporary relief of bronchospasm, acute asthmatic attack, mucosal congestion, hypersensitivity and anaphylactic reactions, syncope due to heart block or carotid sinus hypersensitivity, and to restore cardiac rhythm in cardiac arrest. Ophthalmic preparation is used in management of simple (open-angle) glaucoma, generally as an adjunct to topical miotics and oral carbonic anhydrase inhibitors; also used as ophthalmic decongestant. Relaxes myometrium and inhibits uterine contractions; prolongs action and delays systemic absorption of local and intraspinal anesthetics. Used topically to control superficial bleeding.

|

Special Senses: Nasal burning or stinging, dryness of nasal mucosa, sneezing, rebound congestion. Transient stinging or burning of eyes, lacrimation, browache, headache, rebound conjunctival hyperemia, allergy, iritis; with prolonged use: melanin-like deposits on lids, conjunctiva, and cornea; corneal edema; loss of lashes (reversible); maculopathy with central scotoma in aphakic patients (reversible). Body as a Whole: Nervousness, restlessness, sleeplessness, fear, anxiety, tremors, severe headache, cerebrovascular accident, weakness, dizziness, syncope, pallor, sweating, dyspnea. Digestive: Nausea, vomiting. Cardiovascular: Precordial pain, palpitations, hypertension, MI, tachyarrhythmias including ventricular fibrillation. Respiratory: Bronchial and pulmonary edema. Urogenital: Urinary retention. Skin: Tissue necrosis with repeated injections. Metabolic: Metabolic acidoses, elevated serum lactic acid, transient elevations of blood glucose. Nervous System: Altered state of perception and thought, psychosis.

|

Hypersensitivity to sympathomimetic amines; narrow-angle glaucoma; hemorrhagic, traumatic, or cardiogenic shock; cardiac dilatation, cerebral arteriosclerosis, coronary insufficiency, arrhythmias, organic heart or brain disease; during second stage of labor; for local anesthesia of fingers, toes, ears, nose, genitalia. Safety during pregnancy (category C) or lactation is not established.

|

Assessment & Drug Effects

• Monitor BP, pulse, respirations, and urinary output and observe patient closely following IV administration. Epinephrine may widen pulse pressure. If disturbances in cardiac rhythm occur, withhold epinephrine and notify physician immediately.

• Keep physician informed of any changes in intake-output ratio.

• Use cardiac monitor with patients receiving epinephrine IV. Have full crash cart immediately available.

• Check BP repeatedly when epinephrine is administered IV during first 5 min, then q3–5min until stabilized.

• Advise patient to report to physician if symptoms are not relieved in 20 min or if they become worse following inhalation.

• Advise patient to report bronchial irritation, nervousness, or sleeplessness. Dosage should be reduced.

• Monitor blood glucose & HbA1c for loss of glycemic control if diabetic.

| |

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download